ESPE-ESE 2025 10 - 13 May 2025

Weekly somapacitan is effective and well-tolerated in children with idiopathic short stature: randomized phase 3 trial

Authors :

Jennifer Abuzzahab¹; Andrew Dauber²; Michael Højby³; Haruo Mizuno⁴; Philip Murray^{5, 6}; Moshe Phillip^{7, 8}; Tadej Battelino⁹

Affiliations

View Details Hide Details

Keywords

Rare Endocrine Disorder

Congress poster

Somapacitan